Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Gemcitabine--a safety review

M S Aapro1, C Martin, S Hatty

  • 1Oncology Service, Clinique de Genolier, Geneva, Switzerland.

Anti-Cancer Drugs
|June 13, 1998
PubMed
Summary

Gemcitabine, a nucleoside analog, demonstrates a favorable safety profile in solid tumor treatment. This review of 979 patients shows mild hematological toxicities and rare severe adverse events, indicating good tolerability.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Growth and morphogenesis in Streptomyces.

FEMS microbiology letters·1992
Same author

Malignant lymphoma in a patient with relapsing bronchiolitis obliterans organizing pneumonia.

Chest·1992
Same author

Pharmacokinetics and tissue penetration of a single dose of ceftriaxone (1,000 milligrams intravenously) for antibiotic prophylaxis in thoracic surgery.

Antimicrobial agents and chemotherapy·1992
Same author

Nucleotide sequence of the nfaA gene encoding the antigen 8786 adhesive factor of enterotoxigenic Escherichia coli.

FEMS microbiology letters·1992
Same author

Plant genetics flourishes.

Trends in genetics : TIG·1992
Same author

Relatedness of penicillin-binding protein 1a genes from different clones of penicillin-resistant Streptococcus pneumoniae isolated in South Africa and Spain.

The EMBO journal·1992

Area of Science:

  • Oncology
  • Pharmacology
  • Clinical Trials

Background:

  • Gemcitabine is a nucleoside analog with established efficacy in various solid tumors.
  • Understanding the safety profile of single-agent gemcitabine is crucial for its clinical application.

Purpose of the Study:

  • To comprehensively review the safety profile of gemcitabine as a single agent in patients with solid tumors.
  • To analyze hematological and non-hematological toxicities across multiple clinical studies.

Main Methods:

  • Review of safety data from 22 completed clinical studies involving 979 patients treated with gemcitabine.
  • Analysis of adverse events based on a standard dosing schedule (day 1, 8, 15 q 28 days) and dose range (800-1250 mg/m²).
  • Evaluation of WHO grade 3 and 4 toxicities, including hematological parameters, and non-laboratory adverse events.

Main Results:

  • Gemcitabine exhibited mild hematological toxicity, with low rates of grade 3/4 hemoglobin, leukocyte, neutrophil, and platelet toxicities.
  • Non-laboratory toxicities like infection, nausea/vomiting, and pulmonary toxicity were infrequent (≤1.4% for grade 3/4).
  • Common side effects included transient flu-like symptoms, mild fever, peripheral edema, and mild gastrointestinal/renal changes, rarely clinically significant.

Conclusions:

  • Gemcitabine is well-tolerated as a single agent, characterized by a mild overall toxicity profile.
  • The observed myelosuppression is generally short-lived and of limited clinical significance.
  • The favorable safety profile supports the continued use of gemcitabine in solid tumor treatment regimens.

Related Experiment Videos